1. Home
  2. COHR vs ALNY Comparison

COHR vs ALNY Comparison

Compare COHR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coherent Corp.

COHR

Coherent Corp.

N/A

Current Price

$247.21

Market Cap

44.2B

Sector

Technology

ML Signal

N/A

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

N/A

Current Price

$314.14

Market Cap

52.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
COHR
ALNY
Founded
1971
2002
Country
United States
United States
Employees
N/A
115
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.2B
52.9B
IPO Year
1995
2004

Fundamental Metrics

Financial Performance
Metric
COHR
ALNY
Price
$247.21
$314.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
28
Target Price
$214.25
$472.78
AVG Volume (30 Days)
5.4M
1.0M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
71.74
206.88
EPS
1.95
2.33
Revenue
$1,158,794,000.00
$1,037,418,000.00
Revenue This Year
$21.62
$52.78
Revenue Next Year
$23.75
$31.86
P/E Ratio
$128.56
$137.58
Revenue Growth
19.21
22.88
52 Week Low
$45.58
$205.87
52 Week High
$300.20
$495.55

Technical Indicators

Market Signals
Indicator
COHR
ALNY
Relative Strength Index (RSI) 50.30 37.35
Support Level $170.95 $309.57
Resistance Level $247.15 $333.70
Average True Range (ATR) 19.59 9.15
MACD -3.21 0.76
Stochastic Oscillator 20.13 7.75

Price Performance

Historical Comparison
COHR
ALNY

About COHR Coherent Corp.

Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: